UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000011020 |
|---|---|
| Receipt number | R000012902 |
| Scientific Title | Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer. |
| Date of disclosure of the study information | 2013/06/24 |
| Last modified on | 2017/11/30 18:09:47 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/06/23 17:46:42 | ||
| 2 | Update | 2013/12/23 09:42:41 | Email |
|
| 3 | Update | 2017/11/30 18:09:47 | UMIN ID1 |
